Proxalutamide (HS-10370)
Prostate Cancer
Phase 3Active
Key Facts
About Hansoh Pharma
Hansoh Pharmaceutical Group is one of China's premier pharmaceutical companies, specializing in innovative drug development across oncology, central nervous system disorders, and other therapeutic areas. Founded in 1995, the company has successfully commercialized multiple products in China and is expanding its pipeline with novel small molecules and biologics. Hansoh went public on the Hong Kong Stock Exchange in 2019 and continues to invest heavily in R&D to develop first-in-class and best-in-class therapies.
View full company profileTherapeutic Areas
Other Prostate Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Erleada (apalutamide) | Johnson & Johnson | Approved |
| Nubeqa (darolutamide) | Bayer | Approved |
| Xtandi (enzalutamide) | Astellas Pharma | Approved |
| Darolutamide (Nubeqa) | Orion Corporation | Approved |
| Relacorilant + Enzalutamide | Corcept Therapeutics | Phase 2 |
| NBTXR3 | Nanobiotix | Phase 1/2 |
| Praluzatamab ravtansine (CX-2009) | CytomX Therapeutics | Phase 1/2 |
| Bavdegalutamide (ARV-110) | Arvinas | Phase 2 |
| ARV-766 | Arvinas | Phase 2 |
| Alpha DaRT | Alpha Tau Medical | Phase 1/2 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |